These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34183376)

  • 1. Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and Inhibition.
    Gonzalez E; Jain S; Shah P; Torimoto-Katori N; Zakharov A; Nguyễn ÐT; Sakamuru S; Huang R; Xia M; Obach RS; Hop CECA; Simeonov A; Xu X
    Drug Metab Dispos; 2021 Sep; 49(9):822-832. PubMed ID: 34183376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
    Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
    Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity.
    Lim SYM; Binti Azidin AR; Ung YT; Al-Shagga M; Alshawsh MA; Mohamed Z; Ong CE; Pan Y
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):423-431. PubMed ID: 30306496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of machine learning models for cytochrome P450 3A4, 2D6, and 2C9 inhibition.
    Gong C; Feng Y; Zhu J; Liu G; Tang Y; Li W
    J Appl Toxicol; 2024 Jul; 44(7):1050-1066. PubMed ID: 38544296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.
    Beers JL; Fu D; Jackson KD
    Drug Metab Dispos; 2021 Oct; 49(10):882-891. PubMed ID: 34330718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
    Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
    Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6.
    Manga N; Duffy JC; Rowe PH; Cronin MT
    SAR QSAR Environ Res; 2005; 16(1-2):43-61. PubMed ID: 15844442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
    Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
    Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop.
    Shin YG; Le H; Khojasteh C; Hop CE
    Comb Chem High Throughput Screen; 2011 Nov; 14(9):811-23. PubMed ID: 21605066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
    He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
    Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.
    Ring BJ; Gillespie JS; Binkley SN; Campanale KM; Wrighton SA
    Drug Metab Dispos; 2002 Sep; 30(9):957-61. PubMed ID: 12167559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
    Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
    Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
    Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
    Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
    Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
    Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor.
    Siu YA; Lai WG
    Drug Metab Dispos; 2017 Feb; 45(2):183-189. PubMed ID: 27934636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.